The COVID-19 pandemic has highlighted the importance of international research collaborations to quickly understand and successfully combat emerging and reemerging infectious pathogens globally. As SARS-CoV-2, the causative agent of COVID-19, spread across the world, the number of collaborative international studies defining the impact of COVID-19 have increased rapidly. From these studies, we have gained valuable information regarding the spectrum of clinical disease and the underlying risk factors associated with SARS-CoV-2–induced morbidity and mortality. These data have been important to guide public health interventions globally. However, despite the extensive geographic reach of SARS-CoV-2, low- and middle-income countries (LMICs) and inclusion of subgroups such as children have often been underrepresented within research collaborations. Given the distinct health conditions and resource limitations observed in LMICs, particularly for children, data generated from high-income countries may not be universally valid. Thus, studies conducted in LMICs that focus on COVID-19 outcomes are essential to providing appropriate clinical care and prioritizing interventions of greatest benefit regionally.